Tvardi Therapeutics is trading 12.88% lower at $1.15, tracking biotechnology weakness, elevated Treasury yields, inflation concerns and broader risk-off sentiment.
- Shares fell 15.92% to $1.32 on September 23.
- On September 24, the company reported constructive preclinical STAT3 data for ulcerative colitis. The announcement does not explain the decline and is not a negative catalyst.